



## Discovery and Development of the Novel Antimicrobial Agent

Guest Editors:

**Dr. Zeinab Khalil**

Institute for Molecular  
Bioscience, The University of  
Queensland, St. Lucia, QLD 4072,  
Australia

**Dr. Marcelo Marucci Pereira  
Tangerina**

Department of Botany, Institute  
of Biosciences, University of São  
Paulo, São Paulo 05508-090, SP,  
Brazil

Deadline for manuscript  
submissions:  
**closed (20 January 2024)**

### Message from the Guest Editors

Secondary metabolites, also known as natural products, are produced by a range of species, including bacteria, fungi, and plants. Many medical agents with divergent chemical structures and biological activities such as antibiotic, immunosuppressive, and anti-inflammatory properties have been developed as treatments with potential therapeutic applications for many human diseases. Confronted by the loss of the efficacy of existing antibiotic treatments and the rising incidences of intractable infections and morbidity, there is an urgent need to discover new antibiotic classes that have not been compromised by existing resistance mechanisms. Microbes are a rich source of new drug leads and include polyketides, non-ribosomal peptides, and aminoglycosides. One of the famous microbial polyketides is erythromycin, which was originally isolated from *Streptomyces erythraea*. This antibiotic is prescribed for many human diseases such as syphilis, acne, and whooping cough. Therefore, microbe-derived biologically active natural products and their analogues will continue to inspire the development of new chemical entities.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)